{
    "nctId": "NCT00880711",
    "briefTitle": "Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)",
    "officialTitle": "Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 57,
    "primaryOutcomeMeasure": "Clinical Benefit, defined as the development of at least one of the following stages and holding on for at least 6 month: Complete response, partial response or stable disease",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer\n* Ability to read and write and complete questionnaires\n* Provision of written informed consent\n* Patients who already received a prescription for fulvestrant\n\nExclusion Criteria:\n\n* A subject who does not fulfil all the above mentioned inclusion criteria is not allowed to participate in this NIS",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}